- Home
- CHRS vs JYNT Comparison
CHRS vs JYNT Comparison
Compare CHRS & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- JYNT
- Stock Information
- Founded
- CHRS 2010
- JYNT 2010
- Country
- CHRS United States
- JYNT United States
- Employees
- CHRS N/A
- JYNT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- JYNT Multi-Sector Companies
- Sector
- CHRS Health Care
- JYNT Miscellaneous
- Exchange
- CHRS Nasdaq
- JYNT Nasdaq
- Market Cap
- CHRS 191.3M
- JYNT 154.2M
- IPO Year
- CHRS 2014
- JYNT 2014
- Fundamental
- Price
- CHRS $1.32
- JYNT $11.40
- Analyst Decision
- CHRS Strong Buy
- JYNT Strong Buy
- Analyst Count
- CHRS 4
- JYNT 2
- Target Price
- CHRS $5.38
- JYNT $17.50
- AVG Volume (30 Days)
- CHRS 2.0M
- JYNT 51.3K
- Earning Date
- CHRS 03-12-2025
- JYNT 03-13-2025
- Dividend Yield
- CHRS N/A
- JYNT N/A
- EPS Growth
- CHRS N/A
- JYNT N/A
- EPS
- CHRS N/A
- JYNT N/A
- Revenue
- CHRS $304,340,000.00
- JYNT $120,795,620.00
- Revenue This Year
- CHRS $2.47
- JYNT $3.28
- Revenue Next Year
- CHRS N/A
- JYNT N/A
- P/E Ratio
- CHRS N/A
- JYNT N/A
- Revenue Growth
- CHRS 44.19
- JYNT 5.26
- 52 Week Low
- CHRS $0.66
- JYNT $9.10
- 52 Week High
- CHRS $2.87
- JYNT $17.82
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- JYNT 62.25
- Support Level
- CHRS $1.38
- JYNT $10.08
- Resistance Level
- CHRS $1.60
- JYNT $11.73
- Average True Range (ATR)
- CHRS 0.12
- JYNT 0.51
- MACD
- CHRS -0.03
- JYNT 0.16
- Stochastic Oscillator
- CHRS 1.10
- JYNT 84.65
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.